020 7189 9999

Monday to Friday 7.45am - 6.00pm
Saturday 9.30am - 1.30pm

Bestinvest

Axa Framlington Biotech - Powell to leave

By MARK HINTON 09/08/2007

Axa Framlington Biotech - Powell to leave by Mark Hinton

Gareth Powell resigned from the Axa Framlington Biotechnology fund on the 8th of August 2007 and will move to manage a hedge fund in 3 months time. Previous long standing manager of this fund, Antony Milford, will take over the management in the interim with Deanne Donnigan (also manager of Axa Framlington Health) whilst a permanent replacement is found.

Whilst the team of Milford and Donnigan is recognised as strong in this specialist area, our policy is to suspend the rating pending clarification of who the management team will be in the future.

More Rating changes
 
Email this page to a friend

Please fill in the form below then click Send article.



Market latest

Index Points +/-
FTSE 100 5338.38 1.24%
FTSE 250 10593.00 0.77%
FTSE All Share 2776.65 1.17%
FTSE Euro 100 2025.68 1.17%
S&P 500 1314.49 0.78%
Nasdaq 2841.98 1.12%
Hang Seng 19200.93 0.31%
Nikkei 225 8876.59 0.86%

Values delayed by at least 15 minutes.
Source: Financial Express

The value of your investments and the income from them can go down as well as up, and you can get back less than you originally invested. Past performance or any yields quoted should not be considered reliable indicators of future returns. Before investing in funds please check the specific risk factors on the key features document or refer to our risk warning notice as some funds can be high risk or complex; they may also have risks relating to the geographical area, industry sector and/or underlying assets in which they invest. Prevailing tax rates and relief are dependent on your individual circumstances and are subject to change.

Bestinvest (Brokers) Ltd & Bestinvest (Consultants) Ltd are authorised and regulated by the Financial Services Authority. This site is for UK Investors only

Version: 4.1.1